Hunan Jingfeng Pharmaceutical (000908) — Cash Flow-to-Debt Ratio
Hunan Jingfeng Pharmaceutical (000908) has a Cash Flow-to-Debt Ratio of 0.14x as of September 2025, meaning its operating cash flow of CN¥125.78 Million could theoretically repay 0% of its total liabilities (CN¥915.74 Million) in one year. Explore Hunan Jingfeng Pharmaceutical long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hunan Jingfeng Pharmaceutical Cash Flow-to-Debt Ratio (1999–2024)
Historical debt coverage capacity for Hunan Jingfeng Pharmaceutical across 26 annual periods. Also explore how large is Hunan Jingfeng Pharmaceutical's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Hunan Jingfeng Pharmaceutical (1999–2024)
Year-by-year debt coverage analysis for Hunan Jingfeng Pharmaceutical. For market capitalisation and broader financial context, see Hunan Jingfeng Pharmaceutical market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.01x | CN¥-5.55 Million | CN¥955.11 Million | ▼ -120.1% |
| 2023 | 0.03x | CN¥35.06 Million | CN¥1.21 Billion | ▼ -70.6% |
| 2022 | 0.10x | CN¥123.27 Million | CN¥1.25 Billion | ▲ +16.3% |
| 2021 | 0.08x | CN¥123.83 Million | CN¥1.46 Billion | ▲ +163.9% |
| 2020 | -0.13x | CN¥-271.68 Million | CN¥2.05 Billion | ▼ -981.6% |
| 2019 | 0.02x | CN¥36.17 Million | CN¥2.41 Billion | ▼ -89.9% |
| 2018 | 0.15x | CN¥350.94 Million | CN¥2.37 Billion | ▲ +122.0% |
| 2017 | 0.07x | CN¥151.65 Million | CN¥2.27 Billion | ▲ +1267.6% |
| 2016 | 0.00x | CN¥12.32 Million | CN¥2.52 Billion | ▼ -93.7% |
| 2015 | 0.08x | CN¥92.37 Million | CN¥1.19 Billion | ▼ -65.5% |
| 2014 | 0.22x | CN¥205.93 Million | CN¥919.76 Million | ▲ +2256.1% |
| 2013 | -0.01x | CN¥-3.44 Million | CN¥331.47 Million | ▼ -1371.2% |
| 2012 | 0.00x | CN¥351.50K | CN¥430.29 Million | ▲ +105.0% |
| 2011 | -0.02x | CN¥-6.87 Million | CN¥420.66 Million | ▲ +55.6% |
| 2010 | -0.04x | CN¥-15.21 Million | CN¥413.53 Million | ▼ -111.8% |
| 2009 | -0.02x | CN¥-11.88 Million | CN¥684.14 Million | ▼ -136.4% |
| 2008 | 0.05x | CN¥31.02 Million | CN¥650.60 Million | ▼ -56.5% |
| 2007 | 0.11x | CN¥52.26 Million | CN¥477.43 Million | ▼ -8.1% |
| 2006 | 0.12x | CN¥57.90 Million | CN¥486.08 Million | ▲ +202.2% |
| 2005 | -0.12x | CN¥-59.49 Million | CN¥510.48 Million | ▲ +59.0% |
| 2004 | -0.28x | CN¥-156.37 Million | CN¥550.11 Million | ▼ -811.7% |
| 2003 | 0.04x | CN¥22.51 Million | CN¥563.64 Million | ▼ -21.9% |
| 2002 | 0.05x | CN¥17.59 Million | CN¥343.98 Million | ▼ -79.5% |
| 2001 | 0.25x | CN¥30.50 Million | CN¥122.47 Million | ▲ +296.2% |
| 2000 | -0.13x | CN¥-25.05 Million | CN¥197.38 Million | ▼ -292.2% |
| 1999 | 0.07x | CN¥13.64 Million | CN¥206.51 Million | — |